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In this review, we discuss genetic evidence supporting Guyton’s hypothesis stating that blood pres-
sure control is critically depending on ﬂuid handling by the kidney. The review is focused on the
genetic dissection of sodium and potassium transport in the distal nephron and the collecting duct
that are the most important sites for the control of sodium and potassium balance by aldosterone
and angiotensin II. Thanks to the study of Mendelian forms of hypertension and their corresponding
transgenic mouse models, three main classes of diuretic receptors (furosemide, thiazide, amiloride)
and the main components of the aldosterone- and angiotensin-dependent signaling pathways were
molecularly identiﬁed over the past 20 years. This will allow to design rational strategies for the
treatment of hypertension and for the development of the next generation of diuretics.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Hypertension is the most common disease in the human popu-
lation, affecting over 1 billion individuals worldwide, and is one of
the major treatable risk factors in cardiovascular diseases including
stroke, myocardial infarction, heart and kidney failure. Despite the
importance of hypertension as a cause of cardiovascular-renal dis-
ease, its pathogenesis is largely unknown. Four lines of evidence
have veriﬁed Guyton’s 30 year old hypothesis stating that blood
pressure (BP) is critically dependent on salt handling by the kid-
ney: (i) physiological evidence: the pressure–natriuresis relation-
ship established by Guyton; (ii) pharmacological evidence: the
introduction of diuretics (thiazide) in the early 60 as ﬁrst line
and, for the ﬁrst time, effective treatment of essential hyperten-
sion; (iii) genetic evidence in animal experiments (rodents): kid-
ney cross transplantation between hypertensive strains and their
corresponding ‘‘wild type’’ strains indicated that the hypertensive
phenotype always ‘‘follows the kidney’’ from the hypertensive
strain; (iv) genetic evidence in humans: mutations with Mendelian
transmission in 18 genes have now been identiﬁed as genes caus-
ing a salt loosing (hypotensive) or a salt retaining (hypertensive)
phenotype. All genes map to the renin angiotensin aldosterone sys-
tem (RAAS). Molecular and genetic approaches have begun to de-ﬁne the key players and molecular pathways determining
variations in BP. The major sodium (NKCC2, NCC and ENaC) and
potassium (ROMK) transporters are expressed in the distal neph-
ron and are the targets for all of the clinically useful diuretics –
furosemide/bumetanide inhibit NKCC2, thiazides inhibit NCC and
amiloride blocks the ENaC. Importantly, molecular/genetic ap-
proaches have also begun to deﬁne the signaling pathways regulat-
ing and integrating these cation transporter activities and their
roles in determining blood pressure. Aldosterone and Angiotensin
II signaling pathways are expressed in the distal nephron and some
of their components have been found to be mutated in Mendelian
form of human hypertension (mineralocorticoid receptor MR, the
11b-HSD2 that protects MR from illicit occupation by cortisol,
WNK1, WNK4, Cullin3, KLHL3). Several transgenic mice (classical
transgenic, knock-in and knockout) have been generated to vali-
date and study the role of these key players in both renal salt han-
dling and blood pressure regulation. A number of relevant and
extensive reviews have been published covering different aspects
of the genetics of hypertension in human and animal models [1–
6]. In the present review we will discuss recent advances that have
been made in this ﬁeld focusing on the control of sodium and
potassium balance along the renal distal nephron and the collect-
ing duct that are tightly regulated by aldosterone and angiotensin.
We will focus on experimental evidence obtained by genetic dis-
section of sodium and potassium transport along these nephron
segments using knock out or knock in transgenic mouse models
1930 B.C. Rossier et al. / FEBS Letters 587 (2013) 1929–1941that mimick human salt retaining or salt loosing syndromes with
an hyper- or hypotensive phenotype, respectively. These human
diseases and their corresponding animal models have deﬁned the
most signiﬁcant steps that are limiting in the action of aldosterone
and angiotensin. These limiting steps represent the best drug tar-
gets for the development of novel therapies speciﬁcally for the next
generation of diuretics that remain a class of drugs of major clinical
importance for the treatment of hypertension.
2. Distal nephron and collecting duct: the aldosterone-sensitive
distal nephron
The nephron is the functional unit of the kidney (Fig. 1). In hu-
man, 180 L of ﬂuid is ﬁltered per day through the glomerulus (G).
Around 60% will be reabsorbed in the proximal tubule (PCT and
PST) (2), 30% in the Henle’s loop (TL and TAL) (4), 10% in the Distal
Convoluted Tubule (DCT), the Connecting Tubule (CNT) and the
Collecting Duct (CD) leaving 1.8 L/day of ﬁnal urine. Over 90% of re-
nal ATP is used for ﬂuid reabsorption driven by the Na, K-ATPase.
Sodium and potassium balance are achieved through the ﬁnal reg-
ulation of sodium and potassium transport in the distal nephron
and the collecting duct under hormonal control (aldosterone, vaso-
pressin, angiotensin, insulin, etc.). DCT cells, CNT cells and CD prin-
cipal cells are the main cells involved in hormonal regulation. Most
of the ﬁne regulation of sodium and potassium transport takes
place in the Thick Ascending Limb (TAL) (or Distal Straight Tubule),
the Distal Convoluted Tubule (DCT), the Connecting Tubule (CNT)
that branch 10–12 nephrons onto one collecting duct (CD)
(Fig. 1). Aldosterone is a mineralocorticoid hormone that plays a
critical role in achieving sodium and potassium balance by control-
ling sodium reabsorption and potassium secretion in the kidney.
Glucocorticoid receptor (GR) is ubiquitously expressed in the
glomerulus, the entire nephron and in the collecting duct whereasIN
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Fig. 1. Model of a nephron, the functional unit of the kidney. The nephron is composed o
convoluted tubule (PCT) (2) and proximal straight tubule (PST) (3), the Henle’s loop (Thin
tubule (DCT) (6), the connecting tubule (CNT) (7). 10–12 Nephrons branch on one colle
collecting duct (OMCD) and the inner medullary collecting duct (IMCD). adapted from
glomerulus (G). Around 60% of the ﬁltrate will be reabsorbed in the proximal tubule (P
leaving 1.8 L/day of ﬁnal urine. Over 90% of renal ATP is used for ﬂuid reabsorption driven
regulation of sodium and potassium transport in the distal nephron and the collecting d
CNT cells and CD principal cells are the main cells involved in hormonal regulation. Seethe mineralocorticoid receptor (MR) is expressed in speciﬁc seg-
ments of the nephron: the Thick Ascending Limb (TAL), the Distal
Convoluted Tubule (DCT1 and DCT2), the Connecting Tubule
(CNT) and in the Collecting Duct (CD). Ackerman et al. [7] using
highly speciﬁc antibodies against MR and GR showed that MR is
coexpressed with GR in TAL, DCT, CNT and CD. Mineralocorticoid
speciﬁcity is insured by the coexpression of 11b-HSD2 that metab-
olize cortisol or corticosterone in an inactive metabolite preventing
the illicit occupation of MR by glucocorticoids. The expression of
11b-HSD2 is high in DCT2, CNT and CD but decreases sharply in
DCT1 and TAL. Based on the criteria of MR/11b-HSD2 coexpression,
the Aldosterone-Sensitive Distal Nephron (ASDN) (Fig. 2) has been
deﬁned [8,9] as comprising: the distal part of DCT (DCT2), the CNT
and the CD, anatomically and developmentally distinct from the
nephron but expressing similar regulation by aldosterone. The role
of aldosterone in TAL is not yet well deﬁned but it is interesting to
note that the Angiotensin II receptor (AGTR1) expression fully
overlaps that of MR suggesting that some of the synergistic action
of the two hormones depend on the coexpression of MR and AGTR1
in TAL and downstream to the end of CD. Here, we will focus
primarily on the role of NKCC2, NCC, ROMK, BK and ENaC on so-
dium and potassium transport and their regulatory proteins (MR/
GR, 11b-HSD2, Sgk-1, Nedd4-2, WNK1, WNK4, CUL3, KLHL3)
(Fig. 2).
3. Transporters
3.1. Salt loosing syndromes
3.1.1. Bartter syndrome
As reviewed by Hebert [10] and Jentsch [11] Bartter syndrome
represents a group of autosomal recessive disorders that are char-
acterized by markedly reduced or absent salt transport by the thickCNT
DCT
CCD
IMCD
OMCDo
OMCDi
f a ﬁltering apparatus named the glomerulus (G) (1), the proximal tubule (proximal
descending Limb (TL) (4) and thick ascending limb (TAL) (5)), the distal convoluted
cting duct (CD) (8–11) made of the cortical collecting duct (CCD), outer medullary
Kritz and Kaissling [127]. In human, 180 L of ﬂuid is ﬁltered per day through the
CT and PST) (2), 30% in the Henle’s loop (TL and TAL) (4), 10% in DCT, CNT and CD
by the Na, K-ATPase. Sodium and potassium balance are achieved through the ﬁnal
uct under hormonal control (aldosterone, vasopressin, angiotensin, etc.). DCT cells,
for details linear model in Fig. 2.
Fig. 2. Linear model of the distal nephron and collecting duct. The distal nephron is composed of the straight distal tubule or thick asending limb (TAL), the distal convoluted
tubule (DCT1 and DCT2, the connecting tubule (CNT) and the collecting duct (CD). The aldosterone-sensitive distal nephron (ASDN) is composed of DCT2, CNT and CD that co
express 11b-HSD2 and MR. The corresponding cells (TAL cells, DCT cells, CNT cells, CCD cells are shown above their corresponding nephron segments (drawings adapted from
Kritz an Kaissling [127]. The nephron segment/cell-speciﬁc expression of the relevant transporters and the aldo and angiotensin-dependent signaling pathways are shown
(see text for discussion).
B.C. Rossier et al. / FEBS Letters 587 (2013) 1929–1941 1931ascending limb of Henle. Consequently, individuals with Bartter
syndrome exhibit renal salt wasting and lowered blood pressure,
hypokalemic metabolic alkalosis and hypercalciuria with a variable
risk of renal stones. Five genes have been associated with the dis-
ease (Table 1). These include: (i) SLC12A2, the sodium–potassium–
chloride co-transporter (NKCC2) (type I Bartter); (ii) KCNJ1, the
potassium ion channel (ROMK) (type II Bartter); (iii) CLCNKB, the
basolateral chloride ion channel (ClCKb) (type III Bartter); (iv)
BSND barttin (type IV Bartter). Barttin is a b subunit that is re-
quired for the trafﬁcking of CLCNKB channel to the plasma mem-
brane in both the thick ascending limb and the marginal cells in
the scala media of the inner ear that secrete potassium ion-rich
endolymph. Loss-of-function mutations in BSND thus cause Bartter
syndrome with sensorineural deafness; (v) CASR, a extracellular
calcium ion-sensing receptor. Gain-of-function mutations in this
receptor can result in a Bartter phenotype (type V Bartter) because
activation of this G protein-coupled receptor inhibits salt transport
in the thick ascending limb. As shown in Table 1, transgenic mouse
models mimic Bartter syndrome well type I [12], type II [13], type
IV [14] and to some extent type III [15].
3.1.2. Gitelman syndrome
As recently reviewed by Knoers and Levtchenko [16] Gitelman’s
syndrome (GS), also referred to as familial hypokalemia–hypomag-nesemia, is characterized by hypokalemicmetabolic alkalosis in
combination with signiﬁcant hypomagnesemia and low urinary
calcium excretion. Mutations in the solute carrier family 12, mem-
ber 3 gene, SLC12A3, which encodes the thiazide-sensitive NaCl
cotransporter (NCC), are found in the majority of GS patients
[16]. At present, more than 140 different NCC mutations through-
out the whole protein have been identiﬁed. As shown in Table 1,
the corresponding mouse model shows a mild Gitelman like phe-
notype. In a small minority of GS patients, mutations in the
CLCNKB gene, encoding the chloride channel CLCNKB have been
identiﬁed [16] but the corresponding mouse knock in model has
not yet been engineered. This could help to understand why some
mutations in CLCNKB generate a Bartter like phenotype while oth-
ers generate a Gitelman like phenotype.
3.1.3. PHA-1
As reviewed by Bonny and Rossier [17] and Zennaro et al. [18]
loss-of-function mutations in two key components of the aldoste-
rone response, the mineralocorticoid receptor (MR) and the epithe-
lial sodium channel ENaC, cause type 1 pseudohypoaldosteronism
(PHA-I), a rare genetic disease of aldosterone resistance character-
ized by salt wasting, dehydration, failure to thrive, hyperkalemia
and metabolic acidosis. The renal form of PHA-I is caused by muta-
tions in MR. The phenotype tend to be milder with age [18]. The
Table 1
Phenotype of transgenic mouse models mimicking salt retaining and salt-losing phenotypes along the distal nephron (TAL, DCT,CNT) and collecting duct (CD): transporters.
Human gene Human disease Mouse gene Mouse phenotype Refs.
SLC12A2 Bartter type I Slc12a2
Null allele
Bartter I-like: severe extracellular volume depletion, hyperkalaemia, metabolic acidosis,
hydronephrosis, and high plasma renin and aldosterone concentrations
[12]
KCNj1 Bartter type II Kcnj1
Null allele
Bartter II-like: ROMK-deﬁcient mice exhibit polyuria, natriuresis, and kaliuresis similar to
individuals with type II antenatal Bartter syndrome
[13,45]
CLCNKB Bartter type III Clcnkb
Null allele
The mouse phenotype is distinct from that Bartter III: overt nephrogenic diabetes insipidus with a
decrease of approximately 27% in body weight.
[14,11]
BSND Barrter type IV Bsnd
R8L
Bartter IV-like: hypokalemia, metabolic alkalosis, and decreased NaCl reabsorption in distal
tubules under a low-salt diet. aberrant intracellular localization of R8L barttin
[15]
CASR Bartter type V No mouse model available: expected phenotype is a Bartter-like syndrome associated to
autosomal dominant hypocalcemia
[46,47]
SLC12A3 Gitelman
syndrome
Slc12a3
Null allele
Gitelman-like: subtle perturbations of sodium and ﬂuid volume homeostasis, but renal handling
of Mg2+ and Ca2+ are altered, as observed in Gitelman’s syndrome
[48]
SCNN1A PHA-I
(sytemic)
Scnn1atm1/tm1
Null allele
Severe PHA-1 phenotype with 100% perinatal lethality [19]
SCNN1B PHA-I
(sytemic)
Scnn1b
Null allele
Severe PHA-1 phenotype with 100% perinatal lethality [20]
SCNN1C PHA-I
(sytemic)
Scnn1c
Null allele
Severe PHA-1 phenotype with 100% perinatal lethality [21]
SCNN1A Scnn1a
lox/lox
No phenotype [49]
SCNN1A Scnn1a
lox/lox
Hoxb7Cre
No phenotype as far as sodium and potassium balance
Full protection against lithium induced NDI
[22,23]
SCNN1A Scnn1a
lox/lox
Aqp2Cre
Mild PHA-1 phenotype in adult mice [24]
SCNN1A Scn1a lox/
loxPAX8 rtTA/
LC1
Severe renal PHA-1 phenotype with salt loosing syndrome and life threatening hyperkalaemia.
100% lethality within 10 days without treatment
[26]
SCNN1B Liddle
syndrome
Scnn1bLid/Lid Liddle syndrome-like: salt sensitive hypertension, metabolic alcalosis, hypokalemia [28–30]
KCNMA1
KCNMB1
KCNMB4
No human
disease
reported
Kcnma1
Kcnmb1
Kcnmb4
Disorders observed in BKa1, BKb1 or BKb4 KO mice have shed new insights on the importance of
proper renal K handling for maintaining volume balance and blood pressure
[33–35,50]
SLC26A4 Pendred
syndrome
Slc26a4 Aldosterone and angiotensin II modulate the renal regulation of blood pressure, in part, by
regulating pendrin-mediated Cl- absorption and ENaC-mediated Na+ absorption.
[38,39,41,42]
SLC4A8 No human
disease
Slc4a8 Evidence for a novel electroneutral, amiloride-resistant, thiazide-sensitive, transepithelial NaCl
absorption in mouse CCDs, which persists even with genetic disruption of ENaC
[37,40]
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ENaC subunits. It combines a severe perinatal salt loosing syn-
drome, metabolic acidosis, life threatening hyperkalemia with a
failure to clear ﬂuid from lung (wet lung syndrome) [17]. As shown
in Table 1, constitutive germ line inactivation of either a [19], b
[20] or c [20,21] ENaC subunit in mice causes perinatal lethality
(100% within 48 h after birth) with a renal [19–21] combined with
a lung phenotype [19,21]. The data indicate that there is no redun-
dancy beween any of the 3 homologous subunits of ENaC conﬁrm-
ing in vitro experiments in Xenopus laevis oocytes. The early
lethality precludes any observation of the relative role of each sub-
unit in adult kidney. Nephron and/or collecting duct speciﬁc pro-
motor allows to conditionally inactivate any gene of interest
along the nephron or the collecting duct. This approach allows a
true genetic dissection of the role of ENaC subunits along
the ASDN. Using a HoxB7 promotor exclusively expressed in the en-
tire collecting duct combined to Cre/lox technology, it was possible
to delete conditionally and efﬁciently the ENaC a subunit in this
part of ASDN [22]. Surprisingly neither sodium nor potassium bal-
ance were impaired even when the mice were challenged with low
salt or high potassium diet. The activity of ENaC in CD (at least in
mice) is dispensable and could be compensated by other transport
systems (see below). Interestingly, ENaC expressed in the CD plays
a critical role in lithium-induced nephogenic diabetes insipidus
(NDI) since CD speciﬁc deletion of a ENaC fully protect against lith-
ium toxicity [23]. To investigate the relative importance of ENaC-
mediated sodium absorption in the CNT, mice lacking a ENaC in
the aquaporin 2-expressing CNT and CD were generated. With die-
tary sodium restriction, these mice experienced signiﬁcant weightloss, increased urinary sodium excretion, and hyperkalemia [24].
Plasma aldosterone levels were signiﬁcantly elevated under both
standard and sodium-restricted diets. a ENaC expression within
the CNT/CD is crucial for sodium and potassium homeostasis and
causes signs and symptoms of systemic PHA-1 if missing [24].
However the phenotype was relatively mild compared to the neo-
natal human or mice phenotype raising the question of the impor-
tance of DCT2 the remaining nephron segment still expressing
ENaC under this experimental condition. Since ENaC is co-ex-
pressed with NCC in DCT2 under the control of the aldosterone
dependent-signaling pathway (Fig. 2), this very short segment
could play a major role in achieving sodium and potassium bal-
ance. Recently, it has been possible to induce gene inactivation
along the entire nephron and the collecting duct (excluding the
glomeruli) using a doxycycline-inducible system under the control
of the Pax8 promotor [25]. With this technology it was shown that
the induction of a ENaC deletion in adult kidney causes a severe
salt loosing syndrome with life threatening hyperkalemia and
death if not rescued by a high sodium low potassium diet [26] con-
ﬁrming the key role of DCT2 in ASDN.
3.2. Salt retaining syndromes
3.2.1. Liddle syndrome
Gain-of-function mutations in ENaC b or c subunits cause
pseudoaldosteronism (Liddle’s syndrome), a severe form of salt-
sensitive hypertension, hypokalemia, metabolic alkalosis, low plas-
ma renin activity and suppressed aldosterone secretion with a
Mendelian autosomal dominant mode of transmission [1,27]. As
B.C. Rossier et al. / FEBS Letters 587 (2013) 1929–1941 1933shown in Table 1, Pradervand et al. [28] generated a transgenic
mouse model expressing the human mutation identiﬁed in the
princeps case, i.e., the deletion of a C terminal region of the b sub-
unit (R566Stop) comprising the critical consensus PPXY motif that
bind to the WW domains of an E3 ubiquitylation enzyme (NEDD4L
or Nedd4-2). Under normal salt diet, mice heterozygous (L/+) and
homozygous (L/L) for Liddle mutation (L) develop normally during
the ﬁrst 3 months of life. In these mice, BP is not different from
wild type despite evidence for increased sodium reabsorption in
distal colon and low plasma aldosterone, suggesting chronic hyper-
volemia. Under high salt intake, the Liddle mice develop high BP,
metabolic alkalosis, and hypokalemia accompanied by cardiac
and renal hypertrophy. This animal model reproduces to a large ex-
tent a human form of salt-sensitive hypertension and establishes a
causal relationship between dietary salt, a gene expressed in kid-
ney and hypertension [28]. A subsequent study [29] investigated
the renal sodium transport in vivo, ex vivo (intact perfused tubules),
and in vitro (primary culture of cortical collecting ducts [CCD])
bringing three independent lines of evidence for the constitutive
hyperactivity of ENaC in CCD frommice harboring the Liddle muta-
tion. In another study [30] whole cell currents through epithelial
Na channels (ENaCs) were measured by patch clamp of ex vivo cor-
tical collecting duct (CCD) isolated from mice homozygous for the
Liddle mutation (L/L) and from wild-type (WT) littermates. Miner-
alocorticoid regulation of ENaC is maintained in a mouse model of
Liddle’s syndrome and the highest currents were recorded in L/L
CCD from animal kept under low salt diet. The increase in whole
cell current was attributed to a difference in the density of con-
ducting channels, in agreement with the proposed molecular and
pathogenic mechanism for the Liddle mutation [31,32].
3.3. Potassium channels: ROMK and BK
As discussed above, the critical role of ROMK is underscored by
mutations causing the antenatal Bartter type II, one of the most se-
vere salt loosing syndrome. Holtzclaw et al. [33] have recently re-
viewed the physiological importance of potassium large
conductance calcium-activated channels (Maxi K or BK), and their
potential secretory roles in ﬂow-induced K secretion and in the
control of blood pressure. BK channels are also fundamental to
the control of smooth muscle tone and neuronal excitability. BK
channels can be formed by two subunits: the pore-forming a sub-
unit, which is the product of the KCNMA gene family, a and the
modulatory b subunit product of the KCNMB gene family. Intracel-
lular calcium regulates the physical association between the a and
b subunits. In the kidney the most important BK channels are
theab1 heteromer expressed in the apical membrane of CNT
whereas ab4 heteromers are predominantly expressed in interca-
lated cells (Fig. 2). Constitutive germ line inactivation of BK a sub-
unit results in extreme aldosteronism, hypertension, and an
absence of ﬂow-induced potassium secretion. Inactivation of the
BK b1 subunit results in decreased handling of a potassium load,
increased plasma potassium, mild aldosteronism and hypertension
that is exacerbated by a high potassium diet [34,35]. Inactivation of
BK b4 subunit leads to insufﬁcient potassium handling, high plas-
ma potassium, ﬂuid retention, but with milder hypertension [36].
As discussed by Holtzclaw et al. [33] BK b1 hypertension may be
a ‘‘three-hit’’ hypertension, involving a potassium secretory defect,
elevated production of aldosterone, and increased vascular tone. To
distinguish between these three factors (adrenal, vessels, kidney),
inducible nephron speciﬁc deletion of a1 or b1 or b4 genes will
be highly informative.
We have considered so far the transporters (NKCC2, ROMK, BK,
NCC and ENaC) whose role in sodium and potassium balance is
well established. In most ASDN model little attention is paid to
the role of intercalated cells classically involved in pH homeostasisand acid–base regulation. As reviewed by Eladari and Hubner [37]
and Wall and Pech [38,39], recent data, however indicate, that a
more integrative view of the role of intercalated and principal cells
along the CD and the CNT should be proposed.
3.4. Chloride transporters: SLC26A4 (pendrin) and SLC4A8
As discussed above, the critical role of the chloride channel
CLCNKB and its associated subunit (BDSN/barttin) are underscored
by mutations causing Bartter type 3 and type 4. We will now dis-
cuss the role of two exchangers expressed in intercalated cells that
play a role in blood pressure control. The protein encoded by
SLC4A8 is a membrane protein that functions to transport sodium
and bicarbonate ions across the cell membrane. Leviel et al. [40]
demonstrated that besides the classic electrogenic amiloride-sen-
sitive, ENaC dependent- sodium transport, much of the sodium
absorption in the CCD was actually amiloride-insensitive but thia-
zide-sensitive. The authors demonstrated the presence of an elec-
troneutral, amiloride-resistant, thiazide-sensitive, transepithelial
NaCl absorption in mouse CCDs, which persists even with genetic
disruption of ENaC [40]. The data suggested that the parallel action
of the sodium-driven chloride/bicarbonate exchanger (NDCBE/
SLC4A8) and the sodium-independent chloride/bicarbonate ex-
changer (pendrin/SLC26A4) accounted for the electroneutral thia-
zide-sensitive sodium transport. Further evidence for the
importance of this novel electroneutral transport was obtained
by genetic ablation of SLC4A8 that fully abolished thiazide-sensi-
tive NaCl transport in the CCD. SLC26A4 (solute carrier family 26,
member 4) or pendrin is a membrane protein that functions as
chloride/bicabonate exchanger and mutations in this gene are
associated with Pendred syndrome, the most common form of syn-
dromic deafness, an autosomal-recessive disease. The role of
SLC26A4/pendrin in the regulation of extracellular ﬂuid volume
and blood pressure has recently been reviewed [39,41]. Royaux
et al. reported that Slc26a4(/) mice were severely impaired in
their renal bicarbonate secretion [42]. Next it was shown that a re-
nal phenotype could become unmasked by challenging Slc26a4(/
) mice with the mineralocorticoid DOCP. Mice devoid of pendrin
develop metabolic acidosis and isolated CCD tubule and were un-
able to secrete bicarbonate. Interestingly these mice were ‘‘resis-
tant’’ to DOCP and did not develop salt retention and
hypertension was prevented [43]. Conversely, under salt restric-
tion, Wall et al. reported that Slc26a4 is upregulated and is critical
in the maintenance of acid–base balance and in the renal conserva-
tion of Cl- and water [44].4. Aldosterone and angiotensin signaling pathways
4.1. NKCC2 regulation
As recently reviewed by Ares et al. [51], NKCC2 dependent-so-
dium chloride reabsorption in TAL is subject to exquisite control
by hormones like vasopressin, parathyroid, glucagon, and adrener-
gic agonists that stimulate NaCl reabsorption. Atrial natriuretic
peptides or autacoids like nitric oxide and prostaglandins (PGE2)
inhibit NaCl reabsorption, promoting salt excretion. At least, three
molecular mechanisms: membrane trafﬁcking, phosphorylation,
and protein–protein interactions have recently been described as
mechanisms that modulate NKCC2 activity in TALs and heterolo-
gous expression systems [51].
According to NCBI, SORL1 (SORLA) encodes a mosaic protein
that belongs to at least two families: the vacuolar protein sorting
10 (VPS10) domain-containing receptor family, and the low den-
sity lipoprotein receptor (LDLR) family. In this context, a recent
study [52] (Table 2) shows that the mouse Sorl1 (sorting
1934 B.C. Rossier et al. / FEBS Letters 587 (2013) 1929–1941protein-related receptor with A-type repeats) plays an important
role in functional activation of NKCC2. Sorl1/ mice are unable
to interact with SPAK (Ste-20-related proline–alanine-rich kinase)
that normally allows the proper trafﬁcking of Spak to the apical
membrane of TAL cell and the NKCC2 phosphorylation. The pheno-
type of the Sorl/ mice is a salt losing syndrome mimicking a
Bartter syndrome type 1 indicating that this protein is one of the
limiting factor in this signaling pathway [52]. Until now, no human
SORL1 mutations have been described.
As reviewed by Breyer and Breyer [53], prostaglandin PGE(2) is
a major renal cyclooxygenase metabolite of arachidonate and
interacts with four G protein-coupled E-prostanoid receptors des-
ignated EP(1), EP(2), EP(3), and EP(4). Through these receptors,
PGE(2) modulates renal hemodynamics and salt and water excre-
tion. The authors propose that the capacity of PGE(2) to bidirection-
allymodulate vascular tone and epithelial transport via constrictor
EP(1) and EP(3) receptors versus dilator EP(2) and EP(4) receptors
allows PGE(2) to serve as a buffer, preventing excessive responses
to physiological perturbations. Along this line of thought [54,55], it
has been shown that gene inactivation of the EP(2) receptor lead to
a salt sensitive hypertensive phenotype. EP2/mice develop nor-
mally and have slightly elevated baseline systolic blood pressure.
In EP2/ mice, the characteristic hypotensive effect of intrave-
nous PGE2 infusion was absent; PGE2 infusion instead produced
hypertension. When fed a high salt diet, the EP2/ mice devel-
oped profound systolic hypertension, whereas wild-type mice
showed no change in systolic blood pressure [54]. In another study
however, a reduced blood pressure phenotype was observed [55].
The reason for this discrepancy remains unclear.
4.2. ASDN and RAAS
The role of the renin angiotensin aldosterone system (RAAS) has
been extensively reviewed and the role of each of its component
studied by establishment of transgenic mouse models for renin,
angiotensinogen, ACE, angiotensin II receptor, aldosterone syn-
thase [3–5,56]. In the context of the present review, a few impor-
tant references will be outlined.
4.2.1. Renin
As reviewed by Corvol et al. [3] there are important differences
between human and mouse RAAS. For instance humans have one
renin gene (REN) wheras some mouse strains (i.e., C57BL/6) have
one copy of renin gene (Ren1c) and others (i.e. 1129SV) have two
(Ren1d and Ren2). Deletion of Ren2 does not modify BP [57]
whereas deletion ofRen1d decrease BP in heterozygotes and homo-
zygous females but not in males [58]. In mice, inactivation of any of
the components of the renin-angiotensin system (i.e., renin, angio-
tensin-converting enzyme, angiotensinogen and AT1 receptor) is
dispensable for survival at birth. Animals can survive although
they are more sensitive to salt depletion than the wild type mice.
By contrast, renal tubular dysgenesis (RTD) is a human disease con-
sisting of severe abnormalities of renal tubular development and
resulting in profound anuria and perinatal death. Familial RTD is
an autosomal recessive disease due to genetic defects in any of
the constituents of the renin system [3]. Complete gene inactiva-
tion of the renin system in RTD leads to neonatal anuria and death.
Proximal tubules are almost absent; renal artery hyperplasia is
found in all cases of RTD. An intense stimulation of renin gene
expression is noted in the kidney of patients with mutations affect-
ing angiotensinogen, angiotensin-converting enzyme and AT1
receptor. The more severe phenotype in humans compared to mice
devoid of a functional renin system may be, in part, attributable to
the difference in nephrogenesis between mice and humans. In
mice, nephrogenesis is completed 2 weeks after birth, whereas in
humans it is completed before birth, at 38 weeks of gestation [3].4.2.2. Angiotensinogen
As reviewed by Takahashi [59] and Smithies [5], potentially
causative variations associated with quantitative differences in
the expression of the angiotensinogen gene (AGT) have been iden-
tiﬁed. Experiments to directly test causation are possible in mice is
possible, establishing that blood pressures are indeed altered by
genetic changes in AGT expression (gene disruption ‘‘zero copy’’,
heterozygous mutants ‘‘one copy’’, wild type ‘‘two copies’’, gene
titration by gene duplication ‘‘3–4 copies’’. Thus, angiotensino-
gen-deﬁcient mice generated by homologous recombination in
mouse embryonic stem cells do not produce angiotensinogen in
the liver, resulting in the complete loss of plasma immunoreactive
angiotensin I. The systolic blood pressure of the homozygous mu-
tant mice is drastically reduced by >30% [60]. Gene titration exper-
iment show that blood pressure rises linearly as the number of
copies of the Agt gene increases [61].
4.2.3. Angiotensin converting enzyme (ACE)
Angiotensin-converting enzyme (ACE) is a dipeptidyl carboxy-
peptidase that generates the vasoconstricting peptide angiotensin
II and inactivates the vasodilating peptide bradykinin. The gene
encoding ACE is composed of two homologous regions and codes
for both a somatic and testis isoenzyme. The role of the Ace gene
in blood pressure control and reproduction was investigated using
mice generated to carry an insertional mutation that was designed
to inactivate both forms of Ace[62]. When the Ace gene was dis-
rupted, the BP of heterozygotes was normal in males and lower
in females despite a equal reduction of 50% of plasma enzyme
activity in both gender. When the Ace gene was duplicated with
a corresponding linear increase in ACE activity, there was no
change in BP [62].
4.2.4. Angiotensin II receptor (AGTR1)
Angiotensin II receptors (AGTR) are expressed in tissue com-
partments involved in blood pressure control (heart, kidney, blood
vessels, adrenal glands and brain) [63]. Stimulation of AGTR by
angiotensin II causes potent vasoconstriction, release of aldoste-
rone by the adrenal gland in turn promoting sodium absorption
in ASDN [63]. In the brain Angiotensin II triggers a dramatic hyper-
tensive response while in the kidney it triggers renal vasoconstric-
tion and antinatriuresis. A ﬁrst study showed that pressor
responses to infused angiotensin II were virtually absent in
Agtr1a(/) mice and were qualitatively altered in Agtr1a(+/)
heterozygotes. This study demonstrated clearly that mouse type
1A angiotensin II receptor function is required for vascular and
hemodynamic responses to angiotensin II and that altered expres-
sion of the Agtr1a gene has marked effects on blood pressure [64].
In order to distinguish the physiological role of AGTR in individual
tissue compartment, the authors designed an elegant experimental
approach i.e., a kidney cross transplantation strategy [63,65].
Although actions of the RAAS in a variety of target organs have
the potential to promote high blood pressure and end-organ dam-
age, the authors showed convincingly that angiotensin II caused
hypertension primarily through effects on AGTR1 receptors in the
kidney [65]. Importantly renal AGTR1 receptors were absolutely
required for the development of angiotensin II-dependent hyper-
tension and cardiac hypertrophy [65]. When AGTR1 receptors were
eliminated from the kidney, the residual repertoire of systemic,
extrarenal AGTR1 receptors was not sufﬁcient to induce hyperten-
sion or cardiac hypertrophy [65]. Recently RAS actions in the epi-
thelium of the proximal tubule were shown to have a critical and
non redundant role in determining the level of BP [66]. Abrogation
of Agtr1 angiotensin receptor signaling in the proximal tubule
alone is sufﬁcient to lower BP, despite intact vascular responses.
Elimination of this pathway reduces proximal ﬂuid reabsorption
and alters expression of key sodium transporters, modifying pres-
Table 2
Phenotype of trangenic mouse models mimicking salt retaining and salt loosing phenotypes along the distal nephron (TAL, DCT, CNT) and collecting duct (CD): aldosterone and
angiotensin dependent signaling pathways.
Human gene Human
disease
Mouse gene Mouse phenotype Refs.
SORL1 None
described
Sorl1 (SORLA)
Null allele
Barrter-like: intracellular trafﬁcking of SPAK by the sorting receptor SORLA (i.e., Sorl1) is critical for
proper NKCC2 activation
[52]
PTGER2 Ptger2 Null
allele
PGE2, acting through the EP2 receptor, exerts potent regulatory effects on blood pressure
homeostasis
[53–55]
REN Ren1c Null allele
Ren 2 Null allele
Hypotensive phenotype in females
No BP phenotype
[58,57]
AGT Agt
Null allele
Profound hypotension in angiotensinogen-deﬁcient mice demonstrates an indispensable role for
the renin-angiotensin system in maintaining BP
[60,61]
ACE Ace
Null allele
Heterozygous males but not females have low blood pressures although both male and female
heterozygotes had reduced serum ACE activity.
[62]
AGTR1 Agtr1a
Null allele
Angiotensin II receptor type 1 gene ablation
Hypotensive phenotype and resistance to Angiotensin II administration
[64]
Kidney cross
transplantation
Critical role of the kidney in the pathogenesis of hypertension and its cardiovascular
complications. Evidence supporting Guyton’s hypothesis
[113]
Targeting Agtr1a receptor of the proximal tubule of the kidney decreases BP and could be a useful
therapeutic strategy in hypertension.
[66]
WNK4 Wnk4
hypomorphic
Gitelman-like phenotype: wt WNK4 is proposed to be a positive regulator for the WNK-OSR1/
SPAK-NCC cascade
[68]
STK 39
(SPAK)
Stk 39/SPAK
Disruption of
exon 9 and 10
Gitelman-like phenotype: Stk39/SPAK-null mice have defects of NCC in the kidneys and NKCC1 in
the blood vessels, leading to hypotension through renal salt wasting and vasodilation.
[71]
Stk39/SPAK
kinase-dead ki
SPAK plays an important role in controlling blood pressure in mammals. SPAK inhibitors would be
effective at reducing blood pressure
[72]
WNK4 PHA-II Transgenic
Wnk4 PHAII
PHA-II like: Wnk4 is proposed to be a molecular switch that regulates the balance between NaCl
reabsorption and K + secretion
[69]
WNK4 PHA-II Knock in
Wnk4 D56A/+
PHA-II like: WNK4 mutant activates NCC through activation OSR1-SPAK-NCC phosphorylation
cascade.
[70]
WNK1 KS-Wnk1/ PHA-II like: mild intermediate phenotype [74]
CUL3
KLHL3
PHA-II Cullin 3
Kelch-like 3
No mouse model reported. [76,77]
NR3C2 PHA-I Nrc32 null allele PHA-I like (renal): high perinatal lethality but rescued by saline infusion [81,82]
NR3C2 Nrc32 DCT2 and early CNT can compensate to a large extent deﬁcient ENaC-mediated sodium
reabsorption in late CNT and CD.
[83]
NR3C2 Nrc32 Under a low-salt, tamoxifen induced ablation of MR at the adult stage recapitulates the renal
sodium wasting observed in mice with constitutive early-onset MR ablation.
[84]
NR3C2
(S810L)
MR gain of
function
No mouse model reported. Expected phenotype: salt sensitive hypertension exarcebated during
pregnancy
[85]
Cushing Cushing-like ACTH induced hypertension involves both MR and GR [86]
HSD11B2 AME Hsd11b2 Renal sodium retention remains a key event in apparent mineralocorticoid excess (AME) but that
the accompanying hypertension changes from a renal to a vascular etiology over time.
[89]
HSD11B2 Hsd11b2 Salt sensitive hypertension is mediated by complex interactions between MR and GR in haploid
insufﬁcient mice
[90]
SGK1 Sgk1 Mild PHA-1 like phenotype under salt restriction.
Slight protection against DOCP induced hypertension. Overall, Sgk1 is not absolutely required for
sodium reabsorption and potassium secretion in the ASDN
[94][95,98][114]
Sgk1 Nephron speciﬁc inducible deletion in adult animals generates a mild PHA-1 phenotype under salt
restiction together with low blood pressure
[97]
NEDD4L Nedd4l
Exon 7–9
Salt-, amiloride-sensitive hypertension mimicking some features of Liddle syndrome
No lung phenotype
[99]
Nedd4l
Exon 7–9
Nephron speciﬁc inducible deletion in adult animals generate a novel mild salt sesnitive thiazide-
sensitive, amiloride-insensitive hypertension mimicking some features of PHA-II
[101]
Nedd4l
Exon 15
Lung speciﬁc deletion generates a CFTR like phenotype [100]
Nedd4l
Exon 15
Constitutive germ line KO: severe respiratory distress and perinatal lethality [102]
USP2-45 Usp2-45 USP2 does not play a primary role in the control of sodium balance or blood pressure [109]
TSC22D3 Tsc22d3 GILZ does not play a primary role in the control of sodium balance or blood pressure [112]
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hypertension [66].
4.3. ASDN and NCC
4.3.1. WNK4
PHA-II (or familial hyperkalemic hypertension (FHHt) or Gor-
don syndrome) is a Mendelian form of arterial hypertension that
is partially explained by mutations in WNK1 and WNK4 that lead
to increased activity of NCC in the distal nephron [67]. PHA-II is
characterized by salt-, thiazide-sensitive hypertension, variable
degree of hyperkalemia and metabolic acidosis. The transmissionis autosomal dominant with an important genetic heterogeneity
(4 genes identiﬁed). To study the pathophysiological mechanisms
underlying the human phenotype caused by WNK4 mutations,
WNK4 hypomorphic mice were generated by deleting exon 7 of
the Wnk4 gene [68]. These mice did not show hypokalemia and
metabolic alkalosis, but they did exhibit low blood pressure and in-
creased sodium and potassium excretion under low-salt diet. Phos-
phorylation of OSR1/SPAK and NCC was signiﬁcantly reduced in
the mutant mice as compared with their wild-type littermates.
Protein levels of ROMK and Maxi K (BK) were not changed, but
ENaC appeared to be activated as a compensatory mechanism for
the reduced NCC function [68]. Mutations in the gene encoding
1936 B.C. Rossier et al. / FEBS Letters 587 (2013) 1929–1941the kinase WNK4 cause pseudohypoaldosteronism type II (PHA-II),
a syndrome featuring hypertension and hyperkalemia [67]. Physi-
ology in mice transgenic for genomic segments harboring wild-
type (WT) or PHA-II mutant WNK4 is changed in opposite direc-
tions [69]: PHA-II mice have higher blood pressure, hyperkalemia,
hypercalciuria and marked hyperplasia of the distal convoluted tu-
bule (DCT), whereas the opposite is true in wild type mice. Genetic
deﬁciency for the sodium chloride cotransporter of the DCT (NCC)
reverses phenotypes seen in PHA-II mice, demonstrating that the
effects of the PHA-II mutation are due to altered NCC activity
[69]. To mimic more precisely the molecular pathophysiology of
human PHAII in mice, Wnk4 (D561A/+) knock in mice were gener-
ated [70]. The knock in PHA-II mice showed increased apical
expression of phosphorylated Na–Cl cotransporter (NCC) in the
distal convoluted tubules. Increased phosphorylation of the ki-
nases OSR1 and SPAK was also observed in the knock in mice. Api-
cal localization of the ROMK and transepithelial chloride
permeability in the cortical collecting ducts were not affected in
the knock in mice, whereas activity of ENaC was increased. This in-
crease, however, was not evident after hydrochlorothiazide treat-
ment, suggesting that the regulation of ENaC was not a genetic
but a secondary effect [70]. Overall these two studies nicely estab-
lish mouse models to study the molecular physiopathology of PHA-
II or Gordon syndrome. Small differences between the two studies
are probably due to different methodological approaches (BAC
transgene vs knock in).
4.3.2. STK39 (SPAK)
Serine Threonine kinase 39 (STK39) or Ste20-like proline/ala-
nine-rich kinase (SPAK) encodes a serine/threonine kinase that is
thought to function in the cellular stress response pathway.
STK39/SPAK interacts with WNK kinases to regulate NKCC2 and
NCC. SPAK-null mice were generated by targeting disruption of
exons 9 and 10 of SPAK. Compared with SPAK(+/+) littermates,
SPAK(+/) mice exhibited hypotension without signiﬁcant electro-
lyte abnormalities, and SPAK(/) mice not only exhibited hypo-
tension but also recapitulated Gitelman syndrome with
hypokalemia, hypomagnesemia, and hypocalciuria [71]. To deﬁne
the importance of the WNK/SPAK in regulating blood pressure,
knock in mice in which SPAK cannot be activated by WNKs were
generated [72]. The SPAK knock in animals are viable, but display
signiﬁcantly reduced blood pressure that was salt-dependent.
These animals also have markedly reduced phosphorylation of
NCC and NKCC2 cotransporters at the residues phosphorylated
by SPAK. This was also accompanied by a reduction in the expres-
sion of NCC and NKCC2 protein without changes in mRNA levels.
On a normal sodium diet, the SPAK knock in mice were normoka-
laemic, but developed mild hypokalemia when the renin-angioten-
sin system was activated by a low sodium diet [72].
4.3.3. WNK1
As reviewed by Bergaya et al. [73], the WNK1 gene gives rise to
a ubiquitous kinase (L-WNK1) and to a shorter kinase-defective
isoform, KS-WNK1 (for kidney-speciﬁc WNK1), expressed only in
the distal convoluted tubule (DCT) and connecting tubule (CNT)
(see Fig. 2). WNK1 ﬁrst intron deletion leads to overexpression of
L-WNK1 in the DCT and ubiquitous ectopic expression of KS-
WNK1. The increased expression of L-WNK1 in the DCT results in
increased activity of the Na–Cl cotransporter (NCC) and thus
hypervolemia and hypertension. The mechanisms underlying the
hyperkalemia and metabolic acidosis remain unclear [73]. Hadcho-
uel et al. [74] inactivated KS-WNK1 expressed only in DCT (Fig. 1)
and showed that this isoform is an important regulator of sodium
transport. KS-WNK1(/) mice display an increased activity of
NCC, expressed speciﬁcally in the distal convoluted tubule, where
it participates in the ﬁne tuning of sodium reabsorption [74]. Theauthors suggest that the activation of NCC is not sufﬁcient by itself
to induce a hyperkalemic hypertension andthat the deregulation of
other channels, such as ENaC, is probably required [74]. In another
study Liu et al. [75] came to similar conclusions.
4.3.4. KLHL3 and CULLIN3
Recently two studies using exome sequencing identiﬁed muta-
tions in Kelch-like 3 (KLHL3) [76,77] or CULLIN3 (CUL3) [76] in
PHA-II patients. KLHL3 mutations are either recessive or dominant,
whereas CUL3 mutations are dominant and predominantly de
novo. CUL3 and BTB-domain-containing kelch proteins such as
KLHL3 are components of CULLIN-RING E3 ligase complexes that
ubiquitylate substrates bound to kelch propeller domains. Domi-
nant KLHL3 mutations are clustered in short segments within the
kelch propeller and BTB domains implicated in substrate and cullin
binding respectively [76]. Polymorphisms at KLHL3 were not asso-
ciated with blood pressure [77]. KLHL3 is coexpressed with NCC
and downregulates NCC expression at the cell surface [77]. Both
studies establishes a role for KLHL3–CUL3 as new members of
the complex signaling pathway regulating ion homeostasis in the
distal nephron and indirectly blood pressure [77]. Three publica-
tions have recently identiﬁed WNK4 as a major substrate of the
KLHL3–CUL3 complex [78–80]. Collectively, the data demonstrate
that CUL3-RING ligases that contain KLHL3 target ubiquitylation
of WNK4 regulate WNK4 levels, which in turn regulate levels of
ROMK.
4.4. ASDN and ENaC
4.4.1. MR and GR
Mineralocorticoid receptor (MR)-deﬁcient mice have a normal
prenatal development but die within 10 days after birth from a
salt-losing syndrome mimicking human PHA 1 [81]. Interestingly
this phenotype could be rescued by subcutaneous infusion of sal-
ine and this treatment enables the animals to develop through this
critical phase of life, after which they adapt their oral salt and
water intake to match the elevated excretion rate. However, the re-
nal salt-losing defect persists [82]. Due to the obvious experimen-
tal limitations of germline inactivation of MR, Ronzaud et al. [83]
generated mice with MR deﬁciency in principal cell using the
Cre-loxP system driven by regulatory elements of the mouse aqu-
aporin 2 (AQP2) promotor. This strategy should inactivate MR in
the late portion of CNT and CD (Fig. 2). The authors demonstrated
that inactivation of MR in CD and late CNT can be compensated un-
der standard diet but no longer when sodium supply is limited. Be-
cause the mutant mice show preserved renal ENaC activity, this
study provides evidence that the late distal convoluted tubule
and early CNT can compensate to a large extent deﬁcient ENaC-
mediated sodium reabsorption in late CNT and CD [83]. Since
AQP2 is already expressed during renal development, MR ablation
took place long before the analysis performed at the adult stage
leaving open the possibility of non deﬁned long term compensa-
tory mechanisms. To investigate whether the early onset of MR
ablation affected the adult renal sodium handling, Ronzaud et al.
[84] have recently used a tamoxifen- inducible somatic gene inac-
tivation strategy by developing a transgene expressing the
CreER(T2) fusion protein under control of the regulatory elements
of the AQP2 gene (AQP2CreER(T2)). Under a low-salt diet and at
adult stage, the induced ablation of MR at the adult stage recapit-
ulates the renal sodiumwasting observed in mice with constitutive
early-onset MR ablation [84]. In human, a S810L mutation in the
mineralocorticoid receptor (MR) causes early-onset hypertension
that is markedly exacerbated in pregnancy as described by Geller
et al. [85]. This mutation results in constitutive MR activity and al-
ters receptor speciﬁcity, with progesterone and other steroids lack-
ing 21-hydroxyl groups, normally as MR antagonists, becoming
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have been developed to mimick this highly interesting pathophys-
iological situation.
Experiments in Cushing patients and healthy control subjects
receiving adrenocorticotropic hormone (ACTH) indicate that tran-
sient renal sodium retention may contribute to the generation of
hypertension [86]. Bailey et al. [86] have investigated the effect
of chronic ACTH infusion on renal sodium handling in adult male
C57BL/6J mice using selective antagonists to dissect mineralocorti-
coid and glucocorticoid receptor-mediated pathways. ACTH caused
an increase in blood pressure and a reduction in fractional sodium
excretion associated with enhanced activity of ENaC. ACTH excess
promotes renal sodium reabsorption, contributing to the increased
blood pressure; both glucocorticoid and mineralocorticoid recep-
tor pathways are involved. These in vivo data are interesting and
relevant to the relative occupancy of MR vs GR by aldosterone
and cortisol that is controlled by 11b-HSD2. In vitro studies indi-
cate that aldosterone occupies both MR and GR under physiologi-
cal conditions to mediate the sodium transport response but
cortisol or corticosterone may also occupy MR and GR under ex-
treme stress [87].
4.4.2. HSD11B2 (11b-HSD2)
HSD11B2 (11b-hydroxysteroid dehydrogenase type 2 = 11b-
HSD2) controls ligand access to the mineralocorticoid receptor,
and ablation (or inhibition by drug or toxic) of the enzyme causes
severe hypertension in human (apparent mineralocorticoid exces-
s = AME) [88]. Bailey et al. [89] generated a Hsd11b2 null mouse on
an inbred C57BL/6J genetic background, allowing survival to adult-
hood. Initially, impaired sodium excretion associated with in-
creased activity of the epithelial sodium channel was observed.
Later KO mice had BP approximately 20 mmHg higher on average
compared with wild-type mice but were volume contracted, not
volume expanded as expected. Volume contraction was not attrib-
utable to intrinsic vascular dysfunction but rather to high catechol-
amine levels, an important pathogenic factor since alpha1-
adrenergic receptor blockade rescued the hypertensive phenotype,
suggesting that vasoconstriction contributes to the sustained
hypertension in this model. It was proposed that renal sodium
retention remains a key event in apparent mineralocorticoid ex-
cess but that the accompanying hypertension changes from a renal
to a vascular etiology over time [89]. In a subsequent study Bailey
et al. [90] used mice heterozygote for a null mutation in Hsd11b2 to
deﬁne the mechanisms linking reduced enzyme activity to salt
sensitivity of blood pressure. A high-sodium diet caused a rapid
and sustained increase in blood pressure in heterozygous mice
(leading to increased heart weight) but not in wild-type litter-
mates. Interestingly, mineralocorticoid receptor antagonism par-
tially prevented the increase in heart weight but not the increase
in blood pressure. Glucocorticoid receptor antagonism prevented
the rise in blood pressure suggesting a novel interaction among
11b-HSD2, dietary salt, and circulating glucocorticoids [90].
4.4.3. SGK1
The serum-glucocorticoid induced-kinase 1 (SGK1) belongs to
the superfamily of AGC protein kinase [91]. Sgk1 Is an early aldo-
sterone-induced gene (see review in Refs. [92,93]). No Mendelian
form of human salt-losing or salt retainig syndromes have been
mapped to mutations of the SGK1 gene. However, the physiological
role of Sgk1 has been extensively studied in mouse models in vitro
and in vivo.Wullf et al. [94] showed that under a standard NaCl in-
take, renal water and electrolyte excretion was indistinguishable
between Sgk1(/) mice and wild-type mice. In contrast, dietary
NaCl restriction reveals an impaired abilityof Sgk1(/) mice to
adequately decrease sodium excretion despite increases in plasma
aldosterone levels and proximal-tubular sodium and ﬂuid reab-sorption, as well as decreases in blood pressure and glomerular ﬁl-
tration rate. Overall a mild PHA-1 phenotype was observed. In a
second study, Huang et al. [95] studied the importance of Sgk1 in
renal elimination of potassium. Electrophysiological and immuno-
histochemical studies under high potassium diet indicated that re-
duced epithelial sodium channel ENaC and/or Na, K-ATPase
activity in the aldosterone-sensitive distal nephron accounted for
the impaired response in Sgk1/ and that an enhanced apical
abundance of renal outer medullary potassium channel ROMK
partly compensated for the defect. The authors concluded that
the acute and chronic regulation of renal potassium elimination in-
volves Sgk1. Vallon et al. [96] studied the contribution of Sgk1 to
the regulation of renal function, salt intake, and blood pressure
during DOCA-salt excess in Sgk1 deﬁcient mice. There was no dif-
ference in DOCA salt induced increased blood pressure and in cre-
atinine clearance. A more pronounced increase of proteinuria in
Sgk1(/) mice was observed. Overall the observed phenotype
was mild and the authors concluded that SGK1 contributes to the
stimulation of salt intake, kidney growth, proteinuria, and renal
potassium excretion during mineralocorticoid excess [96]. More
recently, Faresse et al. [97] used a somatic nephron speciﬁc induc-
ible gene deletion strategy to study the role of renal nephron spe-
ciﬁc Sgk1 in adult kidney. Under a standard sodium diet, renal
water and Na/K excretion had a tendency to be higher in doxycy-
cline-treated Sgk1 KO mice compared with control mice. The im-
paired ability of Sgk1 KO mice to retain Na increased
signiﬁcantly with a low-salt diet despite higher plasma aldoste-
rone levels. On a low sodium diet, the Sgk1 KO mice were also
hyperkaliuric and lost body weight. This phenotype was accompa-
nied by a decrease in systolic and diastolic blood pressure. This
phenotype mimics a mild human PHA-1 phenotype indicating that
Sgk1 is, to some extent, limiting in the action of aldosterone in
ASDN. In another study, Fejes-Toth et al. [98] also showed a mild
salt-losing phenotype under salt restriction and concluded that
SGK1 was essential for optimal processing of ENaC but was not re-
quired for activation of the channel by aldosterone [98].
4.4.4. NEDD4L (Nedd4-2)
NEDD4L encodes a member of the Nedd4 family of HECT do-
main E3 ubiquitin ligases. HECT domain E3 ubiquitin ligases trans-
fer ubiquitin from E2 ubiquitin-conjugating enzymes to protein
substrates, thus targeting speciﬁc proteins for lysosomal degrada-
tion. The encoded protein mediates the ubiquitylation of multiple
target substrates and plays a critical role in epithelial sodium
transport by regulating the cell surface expression of the epithelial
sodium channel, ENaC [32]. Single nucleotide polymorphisms in
this gene may be associated with essential hypertension [32]. Shi
et al. [99] generated Nedd4-2 null mice. The knockout mice had
higher BP on a normal diet and a further increase in BP when on
a high-salt diet. Overall, the authors concluded that in vivo
Nedd4-2 is a critical regulator of ENaC activity and BP. The absence
of this gene is sufﬁcient to produce salt-sensitive amiloride sensi-
tive hypertension mimicking Liddle syndrome[99]. This data are
consistent with a genetic interaction between ENaC b or c subunits
and Nedd4-2, in turn, in agreement with a large number of in vitro
expression studies demonstrating biochemical and physiological
interactions between the two proteins [32]. Ronzaud et al. [100]
generated doxycycline-inducible, nephron-speciﬁc Nedd4L KO
mice. Under standard and high sodium diets, conditional KO mice
displayed decreased plasma aldosterone but normal Na/K balance.
Under a high sodium diet, KO mice exhibited hypercalciuria and in-
creased blood pressure, which were reversed by thiazide (but not
amiloride treatment). Unlike the constitutive germ line model by
Shi et al. [99] the results demonstrate that loss of NEDD4-2 in adult
renal tubules causes a new form of mild, salt-sensitive hyperten-
sion without hyperkalemia that is characterized by upregulation
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balance maintained by downregulation of ENaC activity and upreg-
ulation of ROMK, a phenotype approaching more that of a PHA-II
than a Liddle syndrome. The reasons for this difference may be
due to one or a combination of the following factors: (i) the consti-
tutive ‘‘chronic’’ deletion Nedd4L in all organs and tissues could
trigger a number of compensatory mechanisms that could contrib-
ute to the Liddle-like phenotype; (ii) the ‘‘acute’’ deletion (within
2 weeks) of Nedd4-2 exclusively in the nephron could trigger dif-
ferent compensatory mechanisms and unmask an unexpected
but interesting PHA II (normokalemic) phenotype demonstrating
that Nedd4-2 might not only control ENaC activity but also NCC;
(iii) despite of the fact that in the two studies the same ﬂoxed allele
was used (inactivation of exon 6–8), differences in genetic back-
ground and/or recombination efﬁciency in adult versus embryo
could be one of the uncontrolled factors of this kind of experiment;
(iv) the generation of tissue speciﬁc spliced variant at N terminal
start could also be a confounding factor. Along this line, two other
Nedd4L knockout models have been reported. Boase et al. gener-
ated a total knockout of Nedd4L by inactivating Exon 15 and Kim-
ura et al. [101] a lung-speciﬁc KO of exon 15 and downstream
regions of the HECT (catalytic) domain to avoid possible splicing
around the N-terminal start site. Boase et al. [102] observed in-
creased ENaC activity and partial lethality due to premature lung
ﬂuid clearing. Kimura et al. reported the development of a cystic
ﬁbrosis-like lung disease, with airway mucus obstruction, goblet
cell hyperplasia, massive inﬂammation, ﬁbrosis, and death by three
weeks of age. These effects of Nedd4L loss are likely caused by en-
hanced ENaC function as described in cystic ﬁbrosis. The lung de-
fects were rescued with administration of amiloride into the
lungs of young knockout pups via nasal instillation [101]. This is
the ﬁrst demonstration that ENaC activity in the lung is controlled
by E3 ubiquitylation. These lung phenotype(s) were not observed
in the original model of Shi et al., the major difference being the
targeted allele.
4.4.5. USP2-45 (ubiquitin speciﬁc peptidase2–45)
The deubiquitylation (DUB) enzyme USP2-45 is an aldosterone
early induced gene [103,104] and was identiﬁed in the kidney of
animal stimulated by aldosterone for 30 min. USP2-45 is also cy-
cling according to a circadian rhythm. Based on in vitro experiment
[105–107], It was proposed that the effect of aldosterone on the
deubiquitylation of ENaC could be synergistic with the effect of
Sgk1 on Nedd4-2 whereas another study suggested that USP2-45
might down-regulate the aldosterone response by interacting with
the mineralocorticoid receptor [108]. Recently, Pouly et al. [109]
investigated the effect of Usp2 gene inactivation. USP2-45 protein
has a rhythmic expression with a peak at ZT12. Usp2-KO mice did
not show any differences to wild-type littermates with respect to
the diurnal control of Na or K urinary excretion and plasma levels
neither on standard diet, nor after acute and chronic changes to
low and high sodium diets, respectively. Moreover, they had simi-
lar aldosterone levels either at low or high sodium diet. Blood pres-
sure measurements using telemetry did not reveal variations as
compared to control mice. The authors suggest that USP2 does
not play a primary role in the control of sodium balance or blood
pressure [109]. One interpretation of these negative results is
redundancy between DUBs and or interactions with other compen-
satory mechanisms.
4.4.6. TSC22D3 (TSC22 domain family, member 3 or GILZ)
As annotated, the protein encoded by this gene shares signiﬁ-
cantsequence identity with the murine TSC-22 and Drosophila
shs, both of which are leucine zipper proteins, that function as
transcriptional regulators. The expression of this gene is stimulated
by glucocorticoids and interleukin 10, and it appears to play a keyrole in the anti-inﬂammatory and immunosuppressive effects of
this steroid and chemokine.
GILZ was identiﬁed in the transcriptome of a kidney cell line
stimulated by aldosterone [110]. In an in vivo rat model, Muller
et al. [111] showed that the Induction of GILZ may play a permis-
sive role in the enhancement of the early and/or late responses;
these effects may be necessary for a full response but do not by
themselves promote early changes in urinary sodium and potas-
sium excretion.
Suarez et al. [112] used Cre/loxP technology to generate mice
deﬁcient for Tsc22d3-2. Male knockout mice were viable but sur-
prisingly did not show any major deﬁciencies in immunological
processes or inﬂammatory responses. Tsc22d3-2 knockout mice
adapted to a sodium-deprived diet and to water deprivation condi-
tions but developed a subtle deﬁciency in renal sodium and water
handling but, unexpectedly, the analysis of the Tsc22d3-2-deﬁcient
mice demonstrated a previously uncharacterized function of gluco-
corticoid-induced leucine zipper protein in testis development
[112].
5. Conclusions and perspectives
The genetic dissection of sodium and potassium transport along
the ASDN allowed to deﬁne the most important limiting factors
(transporters, hormone receptors, kinases, ubiquitylase) that are
involved in the aldosterone- and angiotensin- dependent signaling
pathways speciﬁcally expressed in the kidney. These limiting fac-
tors are, by deﬁnition, good candidates as drug targets for the
treatment of hypertension. For example, ROMK, BK, Nedd4-2,
WNK1, WNK4, Cullin 3, Kelch like 3, SPAK, ClCK/barttin, pendrin,
SLC4A8 and to some extent Sgk1 are potential receptors for the
development of new antihypertensive drugs. Conversely genetic
evidence in transgenic mouse model indicates that Usp2-45 or
GILZ are not limiting and thus not good potential drug targets.
The genetic dissection has also helped to begin to understand
the molecular mechanisms underlying the ‘‘aldosterone paradox’’
(see recent reviews in references [115,116]). Aldosterone promotes
different and somewhat opposed effects either in promoting potas-
sium secretion (with minimun sodium retention) in case of hyper-
kalaemia or in promoting sodium reabsorption (with minimum
potassium loss) in case of hypovolemia. WNK4 phosphorylation
has been proposed as potential molecular switch [67]. It is likely,
however, that other molecular switches will soon be discovered
(MR phosphorylation? E3 enzyme phophorylation?) and thus
deﬁning two separate phoshorylation states of the signaling cas-
cade(s) triggered by either aldosterone and angiotensin (in pres-
ence of hypovolemia) or aldosterone alone (in presence of
hyperkalemia) that could explain the aldosterone paradox. This
would be a signiﬁcant step for the successful development of the
next generation diuretics that should have the following character-
istics: (i) block synergistically ENaC and NCC; As recently shown by
Soleimani et al. [128] a double knock out of pendrin and NCC
causes severe salt wasting, suggesting that synergism between a
NCC inhibitor combined with a pendrin inhibitor could represent
another potent and novel diuretic regimen without causing hypo-
kalemia for patients with ﬂuid overload, including patients with
congestive heart failure, nephrotic syndrome, diuretic resistance,
or generalized edema. (ii) no change in efﬁcacy in presence of high
salt intake; (iii) no effect on potassium balance (no hypo- or hyper-
kalemia). These ideal diuretics would qualify for the name of anti-
salt pill. As shown in the ALLHAT study [117], the present diuretics
specially the thiazides were unsurpassed in long-term drug adher-
ence, controlling elevated blood pressure and were superior to
other therapies in preventing one or more forms of cardiovascular
events. Thiazides, however, have still signiﬁcant side effects i.e.,
no control of potassium balance (hypokalemia and metabolic
B.C. Rossier et al. / FEBS Letters 587 (2013) 1929–1941 1939alkalosis), increased risk of type 2 diabetes and hyperuricemia. To
minimize the side effects of an anti-salt pill, the following criteria
should be met: (i) pharmacodynamically, the antisalt pill should
bind to a nephron segment/cell speciﬁc receptor with high afﬁnity
(nM range) and high selectivity (no cross reactivity with related
gene products); (ii) pharmacokinetically, the aim would be to max-
imally increase urinary apical drug concentrations in ASDN by ac-
tive secretion of the drug by the proximal tubule.
What are the future developments that could contribute to our
knowledge of ASDN function? The present mouse models have
obvious limitations: (i) despite of the fact that RAAS seem to oper-
ate to a great extent similarly in mouse and humans, the ﬁne reg-
ulation of blood pressure is different (heart rate of 500 beats/
min!); (ii) in in most mouse models, the precise mutation(s) ob-
served in human disease were often not introduced in the mouse
genome due to methodological difﬁculties; (iii) the cardiovascular
phenotyping of the mouse remains challenging; (iv) some pathol-
ogies (for instance nephrotic syndrome) are difﬁcult to reproduce
in mouse but are possible in rats. Before the introduction of trans-
genic mouse models, the best characterised animal model for renal
physiology and pathophysiology was the rat. The recent develop-
ment of the zinc ﬁnger technology should allow, in a near future,
to obtain transgenic rat models that could be useful for drug
development.
Finally, due to space limitations, important signaling pathways
contributing signiﬁcantly to the control of blood pressure could not
be discussed here but should also be considered as a source of no-
vel drug targets for the treatment of hypertension: circadian
rhthythm [118,119], insulin [120], vasopressin [121,122], endothe-
lin [123], ANP [124,125], TGFb [126] to mention the most
important.
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